Curis, Inc. (NASDAQ: CRIS), a drug development company, is focused on utilizing its innovative signaling pathway drug technologies to discover new targeting small molecule drug candidates for cancer. Through the expansion of its drug development efforts in the field of cancer, the company is building upon its previous experiences in targeting signaling pathways to develop next generation targeted cancer therapies. For further information, visit the Company’s web site at www.curis.com.
- 16 years ago
QualityStocks
Curis, Inc. (NASDAQ: CRIS)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Better Choice Company, Inc. (NYSE American: BTTR) Completes Merger with SRx Health, Will Rebrand as SRx Health Solutions Inc.
Better Choice Company (NYSE American: BTTR) announced the closing of its business combination with SRx…
-
Brera Holdings PLC’s (NASDAQ: BREA) S.S. Juve Stabia S.r.l Posts Largest Valuation Percentage Gain; Signals Club’s Growing Competitiveness
Brera Holdings, an Ireland-based, international holding company focused on expanding its global portfolio of men’s…
-
QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Moves Forward to Strengthen the Case for HyBryte(TM)
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is advancing its phase 3 replication study (“FLASH2”)…